Agilent Technologies, Inc. $A Shares Sold by Citigroup Inc.

Citigroup Inc. lowered its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 7.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 245,681 shares of the medical research company’s stock after selling 19,568 shares during the quarter. Citigroup Inc. owned approximately 0.09% of Agilent Technologies worth $31,533,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in A. Brighton Jones LLC grew its stake in Agilent Technologies by 6.1% in the 4th quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company’s stock valued at $626,000 after acquiring an additional 270 shares during the period. Jones Financial Companies Lllp lifted its holdings in Agilent Technologies by 15.9% during the first quarter. Jones Financial Companies Lllp now owns 5,610 shares of the medical research company’s stock valued at $602,000 after purchasing an additional 769 shares in the last quarter. Geneos Wealth Management Inc. grew its position in shares of Agilent Technologies by 54.8% in the first quarter. Geneos Wealth Management Inc. now owns 599 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 212 shares during the period. Acadian Asset Management LLC increased its stake in shares of Agilent Technologies by 16.5% during the first quarter. Acadian Asset Management LLC now owns 5,352 shares of the medical research company’s stock worth $625,000 after purchasing an additional 758 shares in the last quarter. Finally, Sivia Capital Partners LLC acquired a new position in shares of Agilent Technologies during the 2nd quarter worth about $273,000.

Key Agilent Technologies News

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: FDA approval supports diagnostic growth — Agilent’s PD-L1 IHC 22C3 pharmDx (Code SK006) received U.S. FDA authorization, reinforcing the company’s position in companion diagnostics and supporting longer‑term revenue potential. Agilent Technologies, Inc. (A) Sparks Confidence With Latest Approvals
• Positive Sentiment: Analyst sentiment remains constructive — multiple buy/overweight ratings and a median price target near $170 signal upside expectations relative to today’s level, providing a positive backdrop for the stock. Agilent Technologies Inc. (A) Releases Q1 2026 Earnings
• Neutral Sentiment: Guidance broadly in line — Agilent issued Q2 EPS guidance of $1.390–1.420 (consensus ~$1.40) and FY26 EPS of $5.900–6.040 (consensus ~$5.93), with FY revenue guided to ~$7.3–7.5B. The outlook is roughly consistent with Street expectations, which helps stabilize sentiment but limits surprise upside. Agilent reports in-line first quarter, says results hurt by US snowstorm
• Neutral Sentiment: Company cites one-off weather headwind — management said U.S. snowstorms disrupted customer access to labs and hurt Q1 results, which suggests part of the weakness may be temporary. Agilent reports in-line first quarter, says results hurt by US snowstorm
• Negative Sentiment: Small EPS/revenue miss and weaker cash flow — Agilent reported Q1 revenue of ~$1.80B (below the ~$1.81B consensus) and non‑GAAP EPS ~$1.36 (missed by $0.01). Third‑party data highlights declines in operating profit and a sizable drop in cash from operations year‑over‑year, which could concern near‑term margin and free‑cash‑flow expectations. Agilent Technologies Inc. (A) Releases Q1 2026 Earnings: Revenue Up, EPS and Operating Cash Flow Miss

Agilent Technologies Trading Up 0.4%

Shares of Agilent Technologies stock opened at $124.85 on Thursday. The stock has a 50 day moving average of $135.31 and a 200 day moving average of $135.97. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.52 and a current ratio of 1.96. The firm has a market capitalization of $35.31 billion, a price-to-earnings ratio of 27.32, a PEG ratio of 3.61 and a beta of 1.30. Agilent Technologies, Inc. has a fifty-two week low of $96.43 and a fifty-two week high of $160.27.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing the consensus estimate of $1.37 by ($0.01). The business had revenue of $1.80 billion during the quarter, compared to analyst estimates of $1.81 billion. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period last year, the company earned $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. As a group, research analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 22nd. Shareholders of record on Tuesday, March 31st will be paid a dividend of $0.255 per share. This represents a $1.02 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Tuesday, March 31st. Agilent Technologies’s dividend payout ratio is 22.32%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on A shares. Barclays upgraded Agilent Technologies from an “equal weight” rating to an “overweight” rating and set a $165.00 price objective on the stock in a report on Monday, December 15th. UBS Group lifted their price target on Agilent Technologies from $170.00 to $180.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. JPMorgan Chase & Co. increased their price objective on Agilent Technologies from $165.00 to $180.00 and gave the company an “overweight” rating in a research note on Tuesday, November 25th. Bank of America raised their price objective on Agilent Technologies from $150.00 to $165.00 and gave the company a “neutral” rating in a report on Tuesday, November 25th. Finally, Citigroup upped their target price on shares of Agilent Technologies from $165.00 to $185.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $164.50.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.